News - Tecfidera, Tropical diseases

Filter

Popular Filters

1 to 25 of 66 results

Japan’s Eisai joins forces with UK researchers on tropical disease research

Japan’s Eisai joins forces with UK researchers on tropical disease research

20-03-2014

Japanese drug major Eisai has entered a collaboration with the UK’s Liverpool School of Tropical Medicine…

EisaiPharmaceuticalResearchTropical diseases

NICE asks Biogen Idec for more information on Tecfidera

NICE asks Biogen Idec for more information on Tecfidera

21-02-2014

The UK’s National Institute for Health and Care Excellence (NICE) is calling on US biotech firm Biogen…

Biogen IdecBiotechnologyCNS DiseasesRegulationTecfideraUK

Biogen’s MS drug Tecfidera approved in EU

Biogen’s MS drug Tecfidera approved in EU

03-02-2014

US biotech firm Biogen Idec’s Tecfidera (dimethyl fumarate) has been approved by the European Commission…

Biogen IdecBiotechnologyEuropeNeurologicalRegulationTecfidera

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

31-01-2014

Belgium-based VIB, a non-profit research institute in life sciences, and the Center for Drug Design and…

Asia-PacificAstraZenecaIndiaInflammatory diseasesOncologyPharmaceuticalResearchTropical diseases

UCB and Biogen sign Asian license agreement for MS drugs

UCB and Biogen sign Asian license agreement for MS drugs

30-01-2014

Belgian drugmaker UCB and US biotech firm Biogen Idec have signed exclusive agreements granting UCB the…

AlprolixAsia-PacificBiogen IdecBiotechnologyEloctateLicensingNeurologicalPharmaceuticalTecfideraUCB

Biogen Idec beats on sales and earnings, with shinning performance from Tecfidera

Biogen Idec beats on sales and earnings, with shinning performance from Tecfidera

29-01-2014

US biotech firm Biogen Idec reported full year and fourth quarter 2013 results that beat consensus Wall…

Biogen IdecBiotechnologyFinancialTecfidera

Royalty Pharma acquires additional interest in Tecfidera for $510 million

Royalty Pharma acquires additional interest in Tecfidera for $510 million

06-01-2014

US private equity firm Royalty Pharma says that it has acquired an additional interest in the earn-out…

Biogen IdecDermatologicalsFumadermFumapharmLicensingNeurologicalPharmaceuticalRoyalty PharmaTecfidera

Takeda collaboration with Medicines for Malaria Venture

Takeda collaboration with Medicines for Malaria Venture

26-12-2013

Japan’s largest drugmaker Takeda Pharmaceutical has entered into agreements with Medicines for Malaria…

DSM265ELQ300PharmaceuticalResearchTakeda PharmaceuticalsTropical diseases

FDA “Breakthrough Therapy” designation for GSK’s malaria drug tafenoquine; EU Cervarix news

FDA “Breakthrough Therapy” designation for GSK’s malaria drug tafenoquine; EU Cervarix news

22-12-2013

The US Food and Drug Administration has granted “Breakthrough Therapy” designation for tafenoquine,…

CervarixEuropeGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationtafenoquineTropical diseases

IFPMA and the Global Fund collaborate to help protect patients from fake medicines

05-12-2013

The International Federation of Pharmaceutical Manufacturers and Associations and the Global Fund to…

Anti-viralsAntibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceuticalRegulationTropical diseases

Novartis researchers identify new drug target for malaria

Novartis researchers identify new drug target for malaria

28-11-2013

Scientists at Swiss pharma major Novartis have discovered a new drug target for treating malaria, with…

NovartisPharmaceuticalResearchTropical diseases

Biogen prevails in EU exclusivity battle for MS drug Tecfidera

Biogen prevails in EU exclusivity battle for MS drug Tecfidera

25-11-2013

US biotech company Biogen Idec saw its shares leap 10% to an all-time high of nearly $278 on Friday,…

Biogen IdecBiotechnologyEuropeNeurologicalPatentsRegulationTecfidera

New malaria vaccines roadmap targets next generation products by 2030

New malaria vaccines roadmap targets next generation products by 2030

14-11-2013

The world should aim to have vaccines which reduce malaria cases by 75%, and are capable of eliminating…

HealthcarePharmaceuticalResearchRest of the WorldTropical diseasesVaccines

2013 FDA approval rates suggest record year for post-launch success

14-11-2013

A focus on hard to treat or specialist diseases is set to result in record post-launch sales for new…

Biogen IdecFinancialGilead SciencesNorth AmericaPharmaceuticalRegulationsofosbuvirTecfidera

US FDA delays approval of Paladin’s Impavido

US FDA delays approval of Paladin’s Impavido

12-11-2013

Canada-based specialty pharmaceutical company Paladin Labs says that the US Food and Drug Administration…

ImpavidoNorth AmericaPaladin LabsPharmaceuticalRegulationTropical diseases

Eisai enters agreement to develop treatments for neglected tropical diseases

Eisai enters agreement to develop treatments for neglected tropical diseases

11-11-2013

Eisai (TYO: 4523) has entered into a global agreement with the Broad Institute to jointly discover and…

Asia-PacificEisaiNorth AmericaPharmaceuticalResearchTropical diseases

Biogen Idec 3rd-qtr beats on revenues and earnings

Biogen Idec 3rd-qtr beats on revenues and earnings

28-10-2013

US biotech firm Biogen Idec says its net income for the third-quarter of 2013 rose to $487.6 million,…

Biogen IdecBiotechnologyFinancialTecfidera

Vaccine confers long-term protection against cholera

17-10-2013

A clinical study published in the Lancet Infectious Diseases demonstrates for the first time that an…

PharmaceuticalSanofiShanthaTropical diseasesVaccines

New data support GSK plan to file for approval of malaria vaccine in 2014

New data support GSK plan to file for approval of malaria vaccine in 2014

08-10-2013

Results from a large-scale Phase III trial, presented today at the Multilateral Initiative on Malaria…

GlaxoSmithKlinePharmaceuticalRegulationResearchRTS,STropical diseasesVaccines

Biogen Idec presents new Tecfidera data in MS at ECTRIMS

04-10-2013

Biogen Idec presented data showing that Tecfidera continues to offer consistent and strong efficacy combined…

Biogen IdecBiotechnologyNeurologicalResearchTecfidera

Mixed US views on Gilenya, Aubagio and Tecfidera as breakthrough MS drugs

03-09-2013

More than half of surveyed neurologists consider US biotech firm Biogen Idec's (Nasdaq: BIIB) Tecfidera…

AubagioBiogen IdecGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalPricingSanofiTecfidera

Eisai gains WHO prequalification for DEC; launches high-dose Aricept in Korea

27-08-2013

Japanese drug major Eisai (TYO: 4523) has received prequalification from the World Health Organization…

AriceptAsia-PacificdiethylcarbamazineEisaiMarkets & MarketingNeurologicalPharmaceuticalRegulationTropical diseases

Multiple sclerosis market could reach $18.3 billion in 2018

19-08-2013

The multiple sclerosis (MS) market is expected to peak at $18.3 billion in 2018, according to healthcare…

AubagioBiogen IdecFinancialGilenyaGlobalNovartisPharmaceuticalSanofiTecfidera

US orphan designation for DengueCide

12-08-2013

USA-based drug developer NanoViricides (OTC BB: NNVC) says that DengueCide, its drug candidate for the…

DengueCideNanoViricidesNorth AmericaPharmaceuticalRegulationTropical diseases

1 to 25 of 66 results

Back to top